Hls Therapeutics, Inc. · TSX:HLS
Hls Therapeutics — Q1 2024 Earnings Presentation
14 slides from Hls Therapeutics's earnings presentation, May 9, 2024
Slide 1: Q1 Fiscal 2024 Conference Call
Q1 Fiscal 2024 Conference Call May 9, 2024 Craig Millian, CEO John Hanna, Interim CFO TSX - HLS
Slide 2: Forward-Looking Statements
Forward-Looking Statements Certain statements in this presentation are “forward-looking statements”. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, assumptions or future events or performance (often, but not alwa
Slide 3: Q1 2024: Financial Highlights
Q1 2024: Financial Highlights Revenue: March Vascepa/Clozaril net $12.5M sales impacted by order timing Adjusted EBITDA: March ex-factory down 3% yoy $2.7M Cash from operations: April ex-factory up 25% yoy $0.8M Toronto Stock Exchange (TSX) - HLS Provided as part of an oral presentation and qualifie
Slide 4: A New Paradigm in the Treatment of Cardiovascular Risk
A New Paradigm in the Treatment of Cardiovascular Risk Toronto Stock Exchange (TSX) - HLS Provided as part of an oral presentation and qualified by such, contains forward-looking statements, actual results may vary materially; HLS disclaims any duty to update
Slide 5: Prescription Momentum Remains Strong
Prescription Momentum Remains Strong Weekly script data since launch 2500 112% increase 2000 in consistent prescribers* 1500 1000 54% increase in unit demand* 500 0 Sep-20 Nov-20 Sep-21 Nov-21 Sep-22 Nov-22 Sep-23 Nov-23 Mar-20 Apr-20 Jul-20 Jan-21 Mar-21 Apr-21 Jul-21 Jan-22 Mar-22 Apr-22 Jul-22 Ja
Slide 6: HLS Provides Notice of Termination of Pfizer Agreement
HLS Provides Notice of Termination of Pfizer Agreement Rationale Bringing Primary Care 3-point action plan Sales In-house ROI below expectations Complete transition of Greater control, flexibility and primary care sales to HLS in Existing primary care accountability for Vascepa’s 2H 2024 prescribers
Slide 7: Life-changing medicine for Treatment Resistant Schizophrenia
Life-changing medicine for Treatment Resistant Schizophrenia Toronto Stock Exchange (TSX) - HLS Provided as part of an oral presentation and qualified by such, contains forward-looking statements, actual results may vary materially; HLS disclaims any duty to update
Slide 8: Brand Performance Generates Steady Cash Flow
Brand Performance Generates Steady Cash Flow Strategies unique to four US$8.5M US$6.1M geographies Q1 Revenue Direct contribution to Ontario - grow the broader market Adjusted EBITDA in Q1 Quebec - maintain existing patient base >8 Western Canada - increase market share consecutive years of patient
Slide 9: 2024 Guidance Update
2024 Guidance Update Toronto Stock Exchange (TSX) - HLS Provided as part of an oral presentation and qualified by such, contains forward-looking statements, actual results may vary materially; HLS disclaims any duty to update
Slide 10: 2024 Guidance Update
2024 Guidance Update Consolidated Vascepa revenue: Clozaril revenue: Adjusted EBITDA: revenue: $17-$18M ~$40M $17-$19M $60-$62M (CDN $22.5-$24.5M) (unchanged) Prior target: $21M Prior range: Prior range: Royalty revenue: $63.5-$66.5M $20.5-$22.5M $3-$4M (CDN $27.5-$30M) (unchanged) Vascepa goal: pos
Slide 11: Financial Review: Solid Foundation to support our growth
Financial Review: Solid Foundation to support our growth Toronto Stock Exchange (TSX) - HLS Provided as part of an oral presentation and qualified by such, contains forward-looking statements, actual results may vary materially; HLS disclaims any duty to update
Slide 12: Q1 2024: Financial Review
Q1 2024: Financial Review Revenue: $12.5M Operating Expenses Adjusted EBITDA: $2.7M Impact from order timing: ~$0.6M Opex down 3% excluding cost of Direct to brand contribution sales from Clozaril: $6.1M Impact from Clozaril US inventory stocking in Q4 2023: $0.35M Selling and marketing down 6% Dire
Slide 13: Q1 Summary
Q1 Summary 1 Q1 impacted by timing of orders for Clozaril and Vascepa 2 Bringing primary care sales function for Vascepa inhouse 3 Provides HLS with greater control, flexibility and accountability over Vascepa’s performance 4 2024 actions set HLS up for an increasingly profitable product portfolio a
Slide 14: Q1 Fiscal 2024 Conference Call
Q1 Fiscal 2024 Conference Call May 9, 2024 Craig Millian, CEO John Hanna, Interim CFO TSX - HLS